TREMFYA® (guselkumab) receives U.S. FDA approval for adults …
WEBSep 11, 2024 · Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active...
JANSSEN ANNOUNCES U.S. FDA APPROVAL OF TREMFYA™ …
WEBHorsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved TREMFYA™ (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Tremfya Approved for Moderate to Severe Ulcerative Colitis
WEB2 days ago · The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).. The approval was based on data from the phase 2b/3 QUASAR study (ClinicalTrials.gov Identifier: NCT04033445), which evaluated the safety and efficacy of guselkumab, an interleukin-23 antagonist, in patients with moderately ...
First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory …
WEBMay 9, 2023 · The Efficacy and Safety of Guselkumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 3 QUASAR Induction Study. Presented at Digestive Disease Week, May 6-9.
TREMFYA® (guselkumab) demonstrates superiority versus …
WEBWashington, D.C. (May 21, 2024) – Johnson & Johnson today announced the first Phase 3 results for TREMFYA ® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), which demonstrated superiority of both subcutaneous (SC) maintenance doses (200 mg every 4 weeks [q4w] and 100 mg every 8 weeks [q8w]) versus ...
New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis …
WEBOct 23, 2023 · Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results from the Phase 3 QUASAR Induction Study.
TREMFYA® (guselkumab) demonstrates superiority versus …
WEBMay 21, 2024 · Johnson & Johnson today announced the first Phase 3 results for TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn's disease (CD), which demonstrated superiority of...
TREMFYA® (guselkumab) demonstrates superiority versus …
WEBWASHINGTON, May 21, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first Phase 3 results for TREMFYA ® (guselkumab) in adult patients with moderately to severely active Crohn's...
First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory …
WEBMay 9, 2023 · The Efficacy and Safety of Guselkumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 3 QUASAR Induction Study.
New Real-World Data Show TREMFYA® (guselkumab) Was
WEBNov 8, 2023 · New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response...
Skip to content